Enso Ventures

Cognitive Geology Ltd is a specialist software provider based in Edinburgh, United Kingdom, focused on developing geological modeling software for oilfield geologists. Founded in 2014, the company offers innovative solutions that help geologists identify and sequentially eliminate the impacts of various geological processes. Its software addresses the gap between existing vendor-designed tools and the investment decision needs of oil companies, effectively managing uncertainty in subsurface exploration. By facilitating the identification, appraisal, and development of both onshore and offshore conventional and unconventional oil and gas reserves, Cognitive Geology supports geologists in making informed business decisions within the oil industry.

NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.

UltraSoC Technologies is an independent provider of system-on-chip (SoC) infrastructure, facilitating the rapid development of embedded systems utilizing advanced SoC devices. Headquartered in Cambridge, with research and development labs in Colchester, the company specializes in on-chip analytics that enhance debugging and optimization processes. Its innovative infrastructure integrates built-in intelligence to continuously monitor and respond to real-world behavior, allowing designers to efficiently create and refine SoCs while reducing costs. By focusing on these capabilities, UltraSoC supports the evolving needs of embedded system developers.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3). Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers. Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

SRJ Technologies Group is an engineering company based in St Helier, Jersey, specializing in weld-free coupling and leak containment solutions for pipeline and process pipework systems. Established in 2011, the company offers a variety of products, including mechanical couplings, multi-shell repair clamps, BoltEx flange clamps, and bespoke repair units. SRJ Technologies has developed innovative pipeline coupling technologies, including the Snap Ring Joint system, which has received Type Approval for hydrocarbons service. The firm serves multiple industries such as oil and gas, desalination, mining, utilities, shipping, and power generation. Additionally, it provides asset integrity management consulting services to assist clients in optimizing their pipeline systems. With a strong focus on research and development, SRJ Technologies holds intellectual property rights that extend to over seventy countries, enhancing its global market presence.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer treatments. The company's lead candidate, CLR 131, is a phospholipid drug conjugate (PDC) currently undergoing Phase II clinical trials for relapsed or refractory multiple myeloma and various B-cell malignancies, with additional Phase I studies as well. Cellectar also develops CLR 1900, aimed at treating solid tumors, and has established collaborative programs to further advance its PDC technology. These collaborations focus on developing several PDC series targeting different cancer types. The company utilizes a proprietary delivery platform designed to specifically target cancer cells, thereby enhancing therapeutic efficacy and minimizing off-target effects. Founded in 2002 and originally known as Novelos Therapeutics, Cellectar Biosciences is headquartered in Florham Park, New Jersey.

Cambridge Nanotherm Limited specializes in the development and commercialization of nano-ceramic technology tailored for the electronics industry. Founded in 2010 and based in Haverhill, United Kingdom, the company offers innovative solutions such as the NANOTHERM metal-backed printed circuit board, which features a nano-ceramic dielectric layer applied directly onto aluminum substrates. This technology enhances thermal conductivity and dielectric strength, making it particularly suitable for electronic applications. Additionally, Cambridge Nanotherm produces a chip-on-heat sink design specifically for LED light engines, contributing to effective thermal management in LED lighting modules and other electronic devices.

Carbodeon specializes in the development of super-property nanomaterials, particularly focusing on enhancing the surface properties of composite materials. The company's product offerings include nanodiamond particles, marketed under the name uDiamond, which are designed for applications such as metal plating, durable low-friction coatings, and thermal and mechanical enhancements in polymers. These nanodiamonds are engineered to provide exceptional toughness and performance, making them suitable for demanding industrial applications. Additionally, Carbodeon produces Nicanite, a form of graphitic carbon nitride that can be transformed into carbon nitride film coatings, offering unique properties for various uses. Through these innovative materials, Carbodeon aims to improve the longevity and performance of components in industrial manufacturing and appliances.